GlassScriptPhysician profile
Stephen Cary Fox
NPI 1386637338
$3,802.33
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,491 · 2020: $1,293 · 2023: $18.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $434.90 | 2019-2020 | |
| Amgen INC. | $368.61 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $350.46 | 2019-2020 | |
| Incyte Corporation | $300.55 | 2019-2020 | |
| Astellas Pharma US INC | $284.24 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $169.83 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $137.99 | 2019-2020 | |
| Lilly USA, LLC | $110.99 | 2019-2020 | |
| Genzyme Corporation | $105.76 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $105.59 | 2019-2020 | |
| Genentech USA, INC. | $86.77 | 2019-2020 | |
| Celgene Corporation | $79.79 | 2019 | |
| Pfizer INC. | $79.18 | 2019-2020 | |
| Tersera Therapeutics LLC | $74.49 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $71.85 | 2019-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.